CAR-T In Vitro Efficacy Services with OncoSolid™ Kidney Cancer Organoid Models

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Kidney Cancer Organoid Models

Kidney tumors include renal cell carcinoma (RCC), Wilms tumor, and RTCK. RCC makes up 80% of all renal cancer and contains subtypes of clear cell renal cell carcinoma (ccRCC), chromophobe RCC (chRCC), papillary RCC (pRCC), and urothelial carcinoma. With the rapid development of targeted therapies for cancer treatment, a precision model that retains the characteristics of tumor tissue is crucial for personalized medicine. Organoids are three-dimensional, in vitro culture models established to resemble the physiological conditions of tumor patients.

Creative Biolabs provides kidney cancer organoids derived from various sources with/without genetic editing as a promising tool to evaluate tumor responses against CAR-T therapies.

Fig.1 Workflow of CAR-T in vitro anti-tumor efficacy evaluation services with our kidney cancer organoid models. (Li,et al., 2022)

Highlights of the Service

01 Immune components are co-cultured in the organoid model.

02 Renal cancer organoid can be seen after seeding and culturing for a week.

03 Organoid is propagated and passaged with stable biological features.

04 A success rate of at least 70% for cancer organoid establishment.

Culturing Methods Available

With advanced organoid culture techniques, Creative Biolabs provides a high-quality culture system, including various culture methods and optimized culture medium that contains extracellular matrix and specific growth factors for each cancer organoid.

Air-liquid Interface (ALI) System

Inner dish and outer dish system
Retain native cellular complexity

Extracellular Matrix-based Culture System

Classical embed system
Reconstitute system

Microfluidic System

Microfluidic System
Retain cellular diversity and tumor structure

Kidney Organoid Characterization

Based on multiple first-in-class techniques, we can have a deep insight into the established cancer organoid to answer the question of whether they are the proper model of the complex tumor tissue.

Kidney Organoid Characterization

Related CAR-T Products for Anti-tumor Efficacy Tests

With extensive experience in CAR-T therapy development, Creative Biolabs provides a wide range of CAR cell therapy-related products applied for organoid-mediated anti-tumor efficacy tests in vitro. Here are kidney cancer-associated antigens and corresponding CAR-T products on the shelf, please click the link to get more information.

Target Antigen	Target Description	CAR-T Products
AXL	AXL, defined as receptor tyrosine kinases, is over-expressed in multiple cancers, including lung, gastric, pancreatic, and renal cancer. Targeting AXL is a candidate therapy for cancer treatment.	Anti-AXL CAR-T
CAIX	Carbonic Anhydrase IX (CAIX) is a hypoxia-induced enzyme expressed on renal tumor cells, and the expressed is under the control of hypoxia-inducible factor 1 alpha.	Anti-CAIX CAR-T
CD70	CD70 is a type II transmembrane protein that belongs to tumor necrosis factor superfamily 7 (TNFSF7). The significantly elevated expression of cd70 on tumor cells makes it a good target for treatment.	Anti-CD70 CAR-T

Case Study

Published Data: Anti-CD70 CAR-T Cytotoxicity Against Kidney Cancer Organoids
A biobank of patient-derived kidney cancer organoids is established. The established cancer organoids recapitulate the histological and gene mutation features of the primary tumor. CD70 has a high expression in some of the cancer organoids and is regarded as a treatment target. Anti-CD70 CAR construction: CD27-4‐1BB-CD3-zeta
Fig.2 Tumor tissue resembling organoid models are developed and verified for CD70 expression. (Li, et al., 2022)
Fig.3 CAR-T cells show significant cytotoxicity to CD70+ kideney cancer organoids. (Li, et al., 2022) C: TNF‐α and IFN‐γ secretion elevated after co-culturing CAR-T cells with organoids. D: The cleaved‐caspase‐3 activity is increased in RCC organoids after co-culture. E: The proliferation of CAR-T cells is monitored after incubation with RCC organoids.

With extensive experience in immuno-oncology, Creative Biolabs offers innovative strategies and customized services to your objectives. If you are interested in organoid application, please contact us immediately.

References

Calandrini, C.; et al. An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity. Nature communications. 2020, 11(1): 1310.
Esser, L. K.; et al. Cultivation of Clear Cell Renal Cell Carcinoma Patient-Derived Organoids in an Air-Liquid Interface System as a Tool for Studying Individualized Therapy. Frontiers in oncology. 2020, 10: 1775.
Li, Z.; et al. Patient-derived renal cell carcinoma organoids for personalized cancer therapy. Clinical and translational medicine. 2022, 12(7): e970.